There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aerovate Therapeutics (AVTE – Research Report), Calidi Biotherapeutics (CLDI – Research Report) and Mediwound (MDWD – Research Report) with bullish sentiments.
Aerovate Therapeutics (AVTE)
BTIG analyst Julian Harrison maintained a Buy rating on Aerovate Therapeutics yesterday and set a price target of $27.00. The company’s shares closed last Tuesday at $14.50.
According to TipRanks.com, Harrison is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerovate Therapeutics with a $37.50 average price target, implying a 163.2% upside from current levels. In a report issued on November 13, TD Cowen also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Calidi Biotherapeutics (CLDI)
In a report released today, Robert Burns from H.C. Wainwright initiated coverage with a Buy rating on Calidi Biotherapeutics and a price target of $11.00. The company’s shares closed last Tuesday at $1.70, close to its 52-week low of $1.50.
According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Calidi Biotherapeutics with a $10.00 average price target, a 468.2% upside from current levels. In a report issued on November 15, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $9.00 price target.
Mediwound (MDWD)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Mediwound today and set a price target of $26.00. The company’s shares closed last Tuesday at $8.40.
According to TipRanks.com, Ramakanth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Mediwound is a Strong Buy with an average price target of $25.33, which is a 197.6% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVTE:
- Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
- Aerovate completes enrollment for Phase 2b portion of IMPAHCT study
- Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
- Aerovate Therapeutics reports Q3 EPS (71c), consensus (69c)
- Is AVTE a Buy, Before Earnings?
